Bayer commits $2.2 billion to build pharmaceutical manufacturing plant in New Albany, Ohio

Manufacturing facility in New Albany

German chemical and pharmaceutical group Bayer announced on 2 October 2026 that it will invest $2.2 billion (1.95 billion euros) to construct a pharmaceutical manufacturing site in New Albany, Ohio. The company detailed the investment in a corporate statement issued on Friday evening. The new facility will produce both active pharmaceutical ingredients and finished medicinal products for distribution in the United States and international markets. Manufacturing at the New Albany site will focus on therapies for cancer, heart conditions, and kidney diseases. Bayer projects that the site will create 600 jobs in the region and strengthen local economic development. The facility will be integrated into the company's broader industrial network to serve patients across the United States and abroad.

Expansion of US pharmaceutical footprint

The $2.2 billion project builds on previous capital allocations by Bayer across the American healthcare sector. Over the past five years, the German group invested more than $7 billion in pharmaceutical research, development, and manufacturing inside the United States. The planned Ohio site will function as part of a new US-based collaboration network, designed to link scientific research with large-scale industrial manufacturing capabilities. Bayer executives indicated that expanding physical manufacturing infrastructure in Ohio will help meet growing clinical demand while reinforcing the company's domestic operational footprint. The move establishes Bayer as the latest European drugmaker to expand domestic production capacity within the United States.

Phased development and leadership response

Bayer plans to construct and commission the New Albany campus in two distinct stages over the coming years. The first section of the manufacturing plant is scheduled to begin commercial operations in 2031, with the second section entering service in 2034. Bayer chief executive officer Bill Anderson noted the strategic role that the American market plays within the company's global manufacturing footprint.

For Bayer, the United States has long been an important production location and significant innovation center.

Anderson explained that combining specialized facilities with qualified workers will expand the company's ability to deliver therapies.

At the new site, we bring together manufacturing expertise and skilled workers to provide patients in the United States and worldwide with innovative, high-quality medicines.

Anderson emphasized that the capital commitment confirms the company's long-term operational plans in the United States.

Federal trade policy and pharmaceutical tariffs

The investment takes place following policy moves by the administration of US President Donald Trump to encourage domestic pharmaceutical manufacturing. The administration has imposed import tariffs on specific patented drugs manufactured abroad to reduce reliance on foreign production facilities. Furthermore, the White House plans to enact tariffs on imported generic medicines beginning in 2028. Under the administration's tariff structure, pharmaceutical companies that build manufacturing plants within the United States receive lower tariff rates than firms that rely solely on drug imports. These trade policies and border duties have prompted multinational pharmaceutical corporations to reassess their global supply chains and production sites.